Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Clearside Biomedical, Inc. (CLSD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 4 Hutson Nancy J (Director) has filed a Form 4 on Clearside Biomedical, Inc.
Txns: Bought 10,000 shares @ $0.86, valued at $8.6k
09/29/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO, ASRS and OIS Scientific Meetings - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., August 14, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The last several months have been very productive for Clearside with the initiation..."
05/12/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/11/2023 8-K Quarterly results
Docs: "Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical Meetings - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., May 11, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We have delivered a productive start to 2023 as we continue exec..."
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 8-K Quarterly results
03/14/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
Docs: "Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety Data, Durability, and Biologic Effect Over 6 Months - - Continued Growth in Retinal Specialists Trained in Suprachoroidal Space Injection Procedure Using FDA-Approved XIPERE® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 9, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , today reported financial results for the fourth ..."
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/02/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Presentation",
"Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMD - Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment - - Extension Participants Experienced a 77 - 85% Reduction in Treatment Burden Over 6 Months - - Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Mark R. Barakat, M.D. - ALPHARETTA, Ga., February 2, 2023 - Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , annou..."
01/20/2023 4 Ciulla Thomas (Chief Medical Officer) has filed a Form 4 on Clearside Biomedical, Inc.
Txns: Sold 13,700 shares @ $1.47, valued at $20.1k
01/20/2023 4 LASEZKAY GEORGE M (CEO) has filed a Form 4 on Clearside Biomedical, Inc.
Txns: Sold 20,030 shares @ $1.46, valued at $29.2k
01/20/2023 4 Deignan Charles A. (CFO) has filed a Form 4 on Clearside Biomedical, Inc.
Txns: Sold 14,030 shares @ $1.5, valued at $21k
01/11/2023 4 Ciulla Thomas (Chief Medical Officer) has filed a Form 4 on Clearside Biomedical, Inc.
Txns: Sold 2,170 shares @ $1.62, valued at $3.5k
01/06/2023 4 LASEZKAY GEORGE M (CEO) has filed a Form 4 on Clearside Biomedical, Inc.
Txns: Granted 487,500 options to buy @ $1.48, valued at $721.5k
01/06/2023 4 Deignan Charles A. (CFO) has filed a Form 4 on Clearside Biomedical, Inc.
Txns: Granted 187,500 options to buy @ $1.48, valued at $277.5k
01/06/2023 4 Ciulla Thomas (Chief Medical Officer) has filed a Form 4 on Clearside Biomedical, Inc.
Txns: Granted 5,000 shares @ $1.25, valued at $6.3k
Granted 5,000 shares @ $0.95, valued at $4.8k
Granted 187,500 options to buy @ $1.48, valued at $277.5k
01/04/2023 SC 13D/A Hatteras Venture Advisors III, LLC reports a 6.1% stake in CLEARSIDE BIOMEDICAL, INC.
01/04/2023 SC 13G/A WHITMORE BRADFORD T reports a 9.9% stake in Clearside Biomedical, Inc.
12/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/20/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
11/21/2022 4 Hutson Nancy J (Director) has filed a Form 4 on Clearside Biomedical, Inc.
Txns: Bought 30,000 shares @ $1.33, valued at $39.9k
11/09/2022 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy